Phathom Pharmaceuticals

Menlo Park, United States Founded: 2019 • Age: 7 yrs Listed
Therapies for gastrointestinal diseases are developed by Phathom Pharmaceuticals.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals is a publicly listed company based in Menlo Park (United States) founded in 2019 by David Socks. Therapies for gastrointestinal diseases are developed by Phathom Pharmaceuticals. Phathom Pharmaceuticals has raised $90 million across 2 funding rounds from investors including SVB, Janus Henderson Investors and RA Capital. The company has 427 employees. Its chief executive, as recorded, is David Socks. Phathom Pharmaceuticals offers products and services including VOQUEZNA. Its focus areas include Life Sciences, Rare Diseases, Drugs and GI. Its legal entity is PHATHOM PHARMACEUTICALS, INC. Its competitors include Lumena Pharma and Ellodi Pharmaceuticals; 1 of its 2 listed competitors has raised funding.

Company details

Phathom Pharmaceuticals was founded in 2019 and is based in Menlo Park, United States. Operations are centered in the pharmaceutical sector, where gastrointestinal disease treatments are developed. The lead candidate, Vonoprazana potassium-competitive acid blockeris targeted at gastroesophageal reflux disease and erosive esophagitis, with phase II clinical trials completed. Leadership includes David Socks as co-founder and CEO, alongside Terrie Curran as CEO and president.

  • Headquarters Menlo Park, United States
  • Employees 427
  • Founders David Socks
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    ••••••••
  • Website phathompharma.com
  • Social LinkedIn X
  • Legal Name Phathom Pharmaceuticals, Inc.
Operational Areas
Key Metrics
  • Annual Revenue
    $175.11 M (USD)
    216.93
    as on Dec 31, 2025
  • Net Profit
    -$221.25 M (USD)
    33.82
    as on Dec 31, 2025
  • EBITDA
    -$159.35 M (USD)
    42.4
    as on Dec 31, 2025
  • Total Equity Funding
    $90M (USD)

    in 2 rounds

  • Latest Funding Round
    $90M (USD), Series C

    May 2019

  • Investors
    SVB

    & 9 more

  • Employee Count
    427

Products & Services of Phathom Pharmaceuticals

Phathom Pharmaceuticals offers a comprehensive portfolio of products and services, including VOQUEZNA.

VOQUEZNA
Prescription Medicine

Treats acid-related damage and heartburn for GI disorders in adults.

Funding Insights of Phathom Pharmaceuticals

Phathom Pharmaceuticals has successfully raised a total of $90M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $90 million completed in May 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $90M
  • Total Rounds 2
  • Last Round Series C — $90M
  • First Round $50M

    (May 2019)

  • Investors Count 10

All 2 funding rounds of Phathom Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
May 2019$90MSeries C–Frazier Healthcare Partners
May 2019$50MDebt – Conventional––
Valuation history

10 investors in total: 10 institutional.

Investors in Phathom Pharmaceuticals

Phathom Pharmaceuticals has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include SVB, Janus Henderson Investors and RA Capital.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Early-stage life science focused VC firm investing in geographies such as Europe and the US
medicxi.comLondon, United Kingdom
Early stage venture capital firm investing in US
1973abingworth.comLondon, United Kingdom
Diversified investment management firm
2000greenspringassociates.comOwings Mills, United States
Multiple sectors are targeted for venture capital investments.
1934janushenderson.comLondon, United Kingdom
US private equity investments are managed by BVF Partners.
bvflp.comSan Francisco, United States
Investments in multiple sectors are made by Sahsen Ventures.
sahsen.comSeattle, United States
Healthcare sector private equity investments are managed by the firm.
1991frazierhealthcare.comSeattle, United States
Banking services are provided to innovative companies, investors, and individuals.
1983svb.comSanta Clara, United States
RA Capital is engaged in evidence-based investing in healthcare and life sciences.
2004racap.comBoston, United States
Provides grants for conservation, economic development, and social impact programs.
1947rkmf.orgPittsburgh, United States
Premium access

Investor details for Phathom Pharmaceuticals

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Phathom Pharmaceuticals

22 people are tracked at Phathom Pharmaceuticals (11 in leadership, 6 in board & advisors, 5 in team); the tracked headcount is 427.

NameRoleGroup
David Socks
Co-Founder & CEOLeadership
Terrie Curran
CEO & PresidentLeadership
Eckhard Leifke
Chief Medical OfficerLeadership
Christine Fischer
Vice President, Commercial Insights & AnalyticsLeadership
Melissa Tankiewicz
Director, Human Resources HRBPLeadership
Dahua R.
Director Of Sales MarketingLeadership
Barbara Gluck
Director Sales OperationsLeadership
Shawn Peter
Area Sales DirectorLeadership
Julie Israel
Area Sales DirectorLeadership
Joann Napolitano
Director Talent AcquisitionLeadership
Azmi Nabulsi
COOLeadership
Michael Cola
DirectorBoard & advisors
Frank Karbe
DirectorBoard & advisors
Heidi Kunz
DirectorBoard & advisors
Mark Stenhouse
DirectorBoard & advisors
Asit Parikh
DirectorBoard & advisors
Tadataka Yamada
ChairmanBoard & advisors
Erin Maher
Sales Operations ManagerTeam
Dax Davila
Territory Sales RepresentativeTeam
Samantha Stuewer
Territory Sales RepresentativeTeam

2 more people are available in the full profile.

Premium access

Complete people profiles for Phathom Pharmaceuticals

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Phathom Pharmaceuticals

Phathom Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol PHAT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date25 Oct 2019
  • Listed onNASDAQ: PHAT
  • Listed entityPhathom Pharmaceuticals, Inc.
  • Exchange sectorHealth technology
  • ISINUS71722W1071
  • Share price$7.00 (-1.82% on the day) · 2026-10-13
  • Market capitalisation$566.3M
  • EPS (diluted, trailing year)$-1.27
  • Volume (last session)1,947,160

Financials of Phathom Pharmaceuticals

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025$175.1M-$221.2M-$159.3M
2024$55.2M-$334.3M-$276.7M
2023$682,000-$201.6M-$166.7M
2022-$197.7M-$171.8M
2021-$143.9M-$134.6M
Premium access

Detailed financial statements for Phathom Pharmaceuticals

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Phathom Pharmaceuticals

3 dated milestones of Phathom Pharmaceuticals, from founding to its latest funding, stage changes and deals.

  1. Founded Phathom Pharmaceuticals is founded.
  2. Funding First funding round of $50.0M.
  3. IPO Lists on the stock exchange (IPO).

Competitors of Phathom Pharmaceuticals

Phathom Pharmaceuticals has 2 listed competitors in our database, 1 of them funded. They include Lumena Pharma and Ellodi Pharmaceuticals.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
lumenapharma.com2011San Diego, United States$71.05M11
Passionately pursuing better treatments for adults and children with rare liver diseases.
ellodipharma.com2020Ewing Township, United States
Therapeutics for Eosinophilic Esophagitis are developed by Ellodi Pharmaceuticals.
Premium access

Detailed competitors of Phathom Pharmaceuticals

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Phathom Pharmaceuticals

The website of Phathom Pharmaceuticals (phathompharma.com) receives about 9.3K visits a month and ranks #3,173,971 among all websites worldwide, #4,177 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    9.3K

    ▲ 49.1% vs previous month

  • Unique visitors
    2.5K

    per month

  • Global rank
    #3,173,971

    among all websites

  • Category rank
    #4,177

    Health · Biotechnology and Pharmaceuticals

Top companies in Rare Diseases

3 companies that operate in the same segment as Phathom Pharmaceuticals (Rare Diseases) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Gene therapies for rare diseases including retinal dystrophies are developed.
2013Philadelphia, Pennsylvania, United StatesUSD 82.8 MUSD 64.73 M822
Therapeutics for genetic diseases are developed through targeted interventions.
2015Palo Alto, California, United StatesUSD 434.2 MUSD 502.08 M730
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Phathom Pharmaceuticals

Premium access

Complete news archive for Phathom Pharmaceuticals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Phathom Pharmaceuticals

Phathom Pharmaceuticals was founded in 2019.

Phathom Pharmaceuticals is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.

David Socks is the CEO of Phathom Pharmaceuticals, as recorded in our data. They have also founded this company.

Phathom Pharmaceuticals is a funded company, having raised a total of $90M across 2 funding rounds to date. The company's 1st funding round was a Series C of $90M, raised on May 2019.

Phathom Pharmaceuticals has 427 employees.

Annual revenue of Phathom Pharmaceuticals is $175.11M as on Dec 31, 2025.

Phathom Pharmaceuticals was founded in 2019 and is based in Menlo Park, United States. Operations are centered in the pharmaceutical sector, where gastrointestinal disease treatments are developed. The lead candidate, Vonoprazana potassium-competitive acid blockeris targeted at gastroesophageal reflux disease and erosive esophagitis, with phase II clinical trials completed. Leadership includes David Socks as co-founder and CEO, alongside Terrie Curran as CEO and president.

Phathom Pharmaceuticals's top competitors include Lumena Pharma and Ellodi Pharmaceuticals.

Phathom Pharmaceuticals offers VOQUEZNA.

Yes, Phathom Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol PHAT.

Phathom Pharmaceuticals has 10 investors. Key investors include SVB, Janus Henderson Investors, RA Capital, Frazier Healthcare Partners, and Abingworth.

Phathom Pharmaceuticals operates through Phathom Pharmaceuticals, Inc..

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available